Added therapeutic value of new drugs approved in Brazil from 2004 to 2016
Abstract: This study aimed to assess the level of therapeutic innovation of new drugs approved in Brazil over 13 years and whether they met public health needs. Comparative descriptive analysis of therapeutic value assessments performed by the Brazilian Chamber of Drug Market Regulation (CMED) and t...
Main Authors: | Rogério Hoefler, Teresa Leonardo Alves, Hubertus G. Leufkens, Janeth de Oliveira Silva Naves |
---|---|
Format: | Article |
Language: | English |
Published: |
Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz
2019-05-01
|
Series: | Cadernos de Saúde Pública |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2019000605006&lng=en&tlng=en |
Similar Items
-
Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval
by: Lin Song, et al.
Published: (2022-03-01) -
Pharmaceutical lobbying in Brazil: a missing topic in the public health research agenda
by: Francisco José Roma Paumgartten -
Editorial: Women in science—Regulatory science 2021
by: Mette Due Theilade Thomsen, et al.
Published: (2023-03-01) -
Sistema Brasileiro de Informação sobre Medicamentos - SISMED
by: Carlos C. F. Vidotti, et al. -
The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy - DOI: 10.3395/reciis.v2i2.193en
by: Lia Hasenclever, et al.
Published: (2009-03-01)